SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 1 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600 | -53.8% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $1,300 | -26.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,760 | -43.9% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $3,140 | -37.2% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $5,000 | +25.0% | 1,000 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $4,000 | -33.3% | 1,000 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $6,000 | -25.0% | 1,000 | 0.0% | 0.00% | -20.0% |
| Q4 2021 | $8,000 | -11.1% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q3 2021 | $9,000 | -25.0% | 1,000 | 0.0% | 0.01% | -22.2% |
| Q2 2021 | $12,000 | -7.7% | 1,000 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $13,000 | -18.8% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q4 2020 | $16,000 | +77.8% | 1,000 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $9,000 | 0.0% | 1,000 | 0.0% | 0.01% | -20.0% |
| Q2 2020 | $9,000 | +28.6% | 1,000 | -12.5% | 0.01% | +25.0% |
| Q1 2020 | $7,000 | -12.5% | 1,143 | +14.3% | 0.01% | -11.1% |
| Q4 2019 | $8,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
| WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
| Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
| Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
| Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
| Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
| CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
| XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
| Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |